Martin Driscoll, CEO of Javelin Pharmaceuticals, said: “We have taken difficult, but necessary actions, to reduce fixed costs across the organization to conserve and extend valuable development dollars.
“Today’s organizational changes are being effected in support of our priorities to file high quality regulatory submissions in the US and the EU for Dyloject and Ereska in 2009 and consummate successful commercialization partnerships for our late stage acute pain care product portfolio.”